Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment
Combination therapy with inteferon-alpha and ribavirin is an approved therapy for patients with chronic hepatitis C. However, even with the use of pegylated interferon, response rates are still poor in many difficult-to-treat groups, especially with genotype 1 and high viral loads. Retreatment of these patients remains challenging. Newer combinations are being investigated to optimize chances of attaining a sustained response in these groups. Thymosin alpha 1 is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. Herein, we describe two cases of retreatment patients with chronic hepatitis C who have failed prior pegylated interferon and ribavirin therapy. They received triple combination therapies of thymosin alpha 1, pegylated interferon and ribavirin and achieved sustained virological responses. These cases support that thymosin-alpha 1 may increase the efficacy of pegylated interferon plus ribavirin in the treatment of non-responders to previous combination therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
|---|---|
| Enthalten in: |
Gut and liver - 1(2007), 1 vom: 28. Juni, Seite 87-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baek, Yang Hyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic hepatitis C |
|---|
| Anmerkungen: |
Date Completed 14.07.2011 Date Revised 20.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5009/gnl.2007.1.1.87 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM198236441 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM198236441 | ||
| 003 | DE-627 | ||
| 005 | 20240420231835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5009/gnl.2007.1.1.87 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM198236441 | ||
| 035 | |a (NLM)20485665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baek, Yang Hyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2011 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Combination therapy with inteferon-alpha and ribavirin is an approved therapy for patients with chronic hepatitis C. However, even with the use of pegylated interferon, response rates are still poor in many difficult-to-treat groups, especially with genotype 1 and high viral loads. Retreatment of these patients remains challenging. Newer combinations are being investigated to optimize chances of attaining a sustained response in these groups. Thymosin alpha 1 is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. Herein, we describe two cases of retreatment patients with chronic hepatitis C who have failed prior pegylated interferon and ribavirin therapy. They received triple combination therapies of thymosin alpha 1, pegylated interferon and ribavirin and achieved sustained virological responses. These cases support that thymosin-alpha 1 may increase the efficacy of pegylated interferon plus ribavirin in the treatment of non-responders to previous combination therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic hepatitis C | |
| 650 | 4 | |a Nonrespondents | |
| 650 | 4 | |a Peginterferon alpha-2a | |
| 650 | 4 | |a Ribavirin | |
| 650 | 4 | |a Thymosin alpha 1 Introduction | |
| 700 | 1 | |a Lee, Sung Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Yoo, Hyun Seung |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Hyun Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ja Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Young Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ha Youn |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Sang Young |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gut and liver |d 2007 |g 1(2007), 1 vom: 28. Juni, Seite 87-9 |w (DE-627)NLM197725406 |x 2005-1212 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2007 |g number:1 |g day:28 |g month:06 |g pages:87-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5009/gnl.2007.1.1.87 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2007 |e 1 |b 28 |c 06 |h 87-9 | ||